All In Biotech

Drug Trial Radar · NCT02509494

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola

Last checked: Nov 19, 2026Latest source record: Jul 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,023 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,023

Actual

Start

Sep 30, 2015

Primary completion

Jun 28, 2019

Study completion Jul 3, 2019

Sponsor

Lead sponsor
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
London School of Hygiene and Tropical Medicine; Ministry of Health and Sanitation, Sierra Leone; University of Sierra Leone; University of Oxford; Institut National de la Santé Et de la Recherche Médicale, France; Grameen Foundation; World Vision, Ireland
First posted
Jul 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.

Conditions

  • Ebola Virus Disease

Interventions

  • Ad26.ZEBOVBiological

    Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.

  • MVA-BN-FiloBiological

    MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).

  • MenACWYBiological

    MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.

  • PlaceboBiological

    0.9% saline for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8)Time frame: 7 days post dose 1 (Day 8)
  2. Stages 1 and 2: Number of Participants With Solicited Local AEs (Day 64)Time frame: 7 days post dose 2 (Day 64)
  3. Stage 1: Number of Participants With Solicited Local AEs (Day 738)Time frame: 7 days post dose 3 (Day 738)
  4. Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 8)Time frame: 7 days post dose 1 (Day 8)
  5. Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 64)Time frame: 7 days post dose 2 (Day 64)
  6. Stage 1: Number of Participants With Solicited Systemic AEs (Day 738)Time frame: 7 days post dose 3 (Up to Day 738)
  7. Stages 1: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to 36 months
  8. Stages 2: Number of Participants With SAEsTime frame: Up to 24 months
  9. Stage 1: Number of Participants With Unsolicited AEs (Day 759)Time frame: 28 days post booster dose (Day 759)
  10. Stage 1: Number of Participants With Unsolicited AEs (Day 29)Time frame: 28 days post dose 1 (Day 29)
  11. Stage 2: Number of Participants With Unsolicited AEs (Day 29)Time frame: 28 days post dose 1 (Day 29)
  12. Stage 1: Number of Participants With Unsolicited AEs (Day 85)Time frame: 28 days post dose 2 (Day 85)
  13. Stage 2: Number of Participants With Unsolicited AEs (Day 85)Time frame: 28 days post dose 2 (Day 85)
  14. Stage 1: Number of Participants With DeathsTime frame: Up to 36 months
  15. Stage 2: Number of Participants With Deaths (Children and Adolescents)Time frame: Up to 12 months
  16. Stage 2: Number of Participants With Deaths (Adults)Time frame: Up to 24 months
  17. Stage 1: Number of Participants With Immediate Reportable Event (IREs)Time frame: Up to 36 months
  18. Stage 2: Number of Participants With IREs (Children and Adolescents)Time frame: Up to 12 months
  19. Stage 2: Number of Participants With IREs (Adults)Time frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Freetown, Sierra Leone

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.